Experimental Therapies Are Wealth‑Gated

Regulatory paperwork, institutional processes, and cost barriers make access to experimental treatments effectively available only to patients with time, money, and teams to navigate them. That dynamic slows clinical progress and concentrates survival chances among the well‑resourced rather than the clinically needy. — This reframes debates about clinical trials and approval rules as questions of distributive justice and innovation policy, with implications for how we regulate AI‑driven personalized medicine.